About Aqua Pharm
Aqua Pharm is a company based in West Chester (United States) founded in 2004 was acquired by Almirall in December 2013. Aqua Pharm has raised $53.67 million across 1 funding round from investors including Almirall and RoundTable Healthcare Partners. The company has 100 employees as of December 31, 2017. Aqua Pharm operates in a competitive market with competitors including Revance Therapeutics, Hugel, Dermavant, Sol-Gel Technologies and SkinMedica, among others.
- Headquarter West Chester, United States
- Employees 100 as on 31 Dec, 2017
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Aqua Pharmaceuticals, Llc
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Aqua Pharm
Aqua Pharm has successfully raised a total of $53.67M through 1 strategic funding round. The most recent funding activity was a Series C round of $53.67 million completed in June 2010. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Aqua Pharm
Aqua Pharm has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Almirall and RoundTable Healthcare Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare companies are built and supported through strategic investments.
|
Locked | Locked | Locked | |
|
Generic finished formulations are manufactured and commercialized by Almirall.
|
Locked | Locked | Locked |
Investor details for Aqua Pharm
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Aqua Pharm
Investment portfolio details for Aqua Pharm
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Aqua Pharm
Detailed financials for Aqua Pharm
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Aqua Pharm Comparisons
Peer comparison for Aqua Pharm
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Aqua Pharm
Aqua Pharm operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Revance Therapeutics, Hugel, Dermavant, Sol-Gel Technologies and SkinMedica, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Neurotoxin products for aesthetic and therapeutic skin treatments are developed.
|
|
| Locked | Locked | Locked |
Therapeutics in aesthetics are developed, including botulinum toxin products.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for inflammatory skin diseases are developed.
|
|
| Locked | Locked | Locked |
Developing topical drug products for the treatment of rosacea, acne and interdigital tinea pedis.
|
|
| Locked | Locked | Locked |
Skin care products are developed and manufactured by SkinMedica.
|
|
| Locked | Locked | Locked |
Plant-derived collagen is developed for tissue repair and 3D bioprinting.
|
Detailed competitors of Aqua Pharm
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Aqua Pharm
Complete news archive for Aqua Pharm
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Aqua Pharm
Aqua Pharm was founded in 2004 and raised its 1st funding round 6 years after it was founded.
Aqua Pharm is headquartered in West Chester, United States. It is registered at West Chester, Pennsylvania, United States.
Ron Menezes is the current CEO of Aqua Pharm.
Aqua Pharm is a funded company, having raised a total of $53.67M across 1 funding round to date.
As of Dec 31, 2017, the latest employee count at Aqua Pharm is 100.
Founded in 2004, Aqua Pharm operates from West Chester, United States, as a provider in the pharmaceutical sector focused on dermatological treatments. Drugs are marketed for conditions including impetigo, acne vulgaris, actinic keratoses, seborrheic dermatitis, atopic dermatitis, and corticosteroid-responsive dermatoses. Key products encompass Altabax, Veltin, Acticlate, Fluoroplex, Xologel, Verdeso, Monodox, and Cordran, serving as primary or adjunctive therapies in this specialty area.
Aqua Pharm's top competitors include Revance Therapeutics, Dermavant and Collplant.
Aqua Pharm has 2 investors. Key investors include Almirall, and RoundTable Healthcare Partners.